TREACE MEDICAL CONCEPTS, INC.
Qualité des données : 100%
TMCI
NASDAQ
Manufacturing
Measuring & Analyzing Instruments
1,81 €
▲
0,28 €
(18,30%)
Cap. Boursière: 98,15 M
Prix
1,52 €
Cap. Boursière
98,15 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Revenue grew 22,51% annually over 5 years — strong growth
Negative free cash flow of -29,49 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 20,92%
Capital efficient — spends only 6,36% of revenue on capex
Croissance
Revenue Growth (5Y)
22,51%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)1,59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-63,17%
En dessous de la moyenne du secteur (-54,01%)
ROIC-26,48%
Net Margin-27,74%
Op. Margin-25,46%
Sécurité
Debt / Equity
0,62
Au-dessus de la moyenne du secteur (0,30)
Current Ratio3,37
Interest Coverage-10,18
Valorisation
PE (TTM|NTM)
-1,66 | -2,01
En dessous de la moyenne du secteur (-1,49)
P/B Ratio1,10
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1385 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -1,7 | -1,5 |
| P/B | 1,1 | 1,6 |
| ROE % | -63,2 | -54,0 |
| Net Margin % | -27,7 | -41,5 |
| Rev Growth 5Y % | 22,5 | 1,8 |
| D/E | 0,6 | 0,3 |
Objectif de Cours des Analystes
4 analystes
Hold
Actuel
1,81 €
Objectif
4,25 €
2,00 €
4,00 €
7,00 €
Prévisions
P/E Prévisionnel
-2,01
BPA Prévisionnel
-0,90 €
CA Est.
222,80 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-0,90 €
-0,90 € – -0,90 €
|
222,80 M | 1 |
| FY2026 |
-0,91 €
-0,91 € – -0,91 €
|
205,92 M | 1 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,29 €
-0,29 € – -0,29 €
|
44,23 M | 1 |
| 2026 Q1 |
-0,31 €
-0,31 € – -0,31 €
|
46,27 M | 1 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,14 € | -0,08 € | +44,1% |
| Q32025 | -0,27 € | -0,22 € | +18,2% |
| Q22025 | -0,29 € | -0,26 € | +9,8% |
| Q12025 | -0,30 € | -0,25 € | +18,3% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,59% | Revenue Growth (3Y) | 6,61% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 22,51% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 212,69 M | Net Income (TTM) | -59,00 M |
| ROE | -63,17% | ROA | -29,28% |
| Gross Margin | 79,81% | Operating Margin | -25,46% |
| Net Margin | -27,74% | Free Cash Flow (TTM) | -29,49 M |
| ROIC | -26,48% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,62 | Current Ratio | 3,37 |
| Interest Coverage | -10,18 | Asset Turnover | 1,06 |
| Working Capital | 97,09 M | Tangible Book Value | 69,01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,66 | Forward P/E | -2,01 |
| P/B Ratio | 1,10 | P/S Ratio | 0,46 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0,44 | Fwd Earnings Yield | N/A |
| FCF Yield | -30,04% | ||
| Market Cap | 98,15 M | Enterprise Value | 145,79 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,93 | Revenue / Share | 3,29 |
| FCF / Share | -0,46 | OCF / Share | -0,25 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 6,36% | FCF Conversion | 49,98% |
| SBC-Adj. FCF | -63,66 M | Growth Momentum | -20,92 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 212,69 M | 209,36 M | 187,12 M | 141,84 M | 94,42 M |
| Net Income | -59,00 M | -55,74 M | -49,53 M | -42,82 M | -20,55 M |
| EPS (Diluted) | -0,93 | -0,90 | -0,81 | -0,77 | — |
| Gross Profit | 169,75 M | 168,26 M | 151,94 M | 114,32 M | 76,59 M |
| Operating Income | -54,15 M | -55,69 M | -51,43 M | -34,84 M | -16,51 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 20,28 M | 20,59 M | 15,44 M | 13,58 M | 10,20 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 10,62 M | 8,42 M | 5,35 M | 2,13 M | 685 000,0 |
| Interest Expense | 5,32 M | 5,26 M | 5,17 M | 4,40 M | 4,06 M |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 190,58 M | 217,09 M | 251,91 M | 159,02 M | 140,82 M |
| Total Liabilities | 103,25 M | 104,20 M | 113,97 M | 98,50 M | 47,75 M |
| Shareholders' Equity | 87,33 M | 112,89 M | 137,94 M | 60,53 M | 93,07 M |
| Total Debt | 57,33 M | 53,31 M | 53,01 M | 52,71 M | 29,37 M |
| Cash & Equivalents | 10,71 M | 11,35 M | 12,98 M | 19,47 M | 105,83 M |
| Current Assets | 132,05 M | 161,40 M | 198,36 M | 133,40 M | 137,97 M |
| Current Liabilities | 30,64 M | 34,93 M | 45,03 M | 30,25 M | 18,21 M |
{"event":"ticker_viewed","properties":{"ticker":"TMCI","listing_kind":"stock","pathname":"/stocks/tmci","exchange":"NASDAQ","country":"US"}}